Related Experiment Videos
An alternative cost effectiveness analysis of ThinPrep in the Australian setting
A Munro Neville1, Michael A Quinn
1Pretium, Sydney, Australia. munro.neville@pretium.com.au
Summary
Liquid-based cytology (LBC) screening for cervical cancer in Australia offers significant clinical and economic advantages over conventional Pap smears. This advanced screening method promises improved detection rates and substantial healthcare savings.
Area of Science:
- Health economics
- Medical technology assessment
- Cervical cancer screening
Background:
- Concerns exist regarding medical technology evaluations in Australia.
- Liquid-based cytology (LBC) is widely adopted globally but rejected for public funding in Australia by MSAC.
- LBC has seen significant private sector uptake in Australia.
Purpose of the Study:
- To evaluate the clinical and economic impact of LBC for average-risk Australian women.
- To assess LBC from a public healthcare budget perspective.
Main Methods:
- Utilized the MSAC health economic model.
- Incorporated international data from a review article.
- Analyzed biennial cervical screening program costs and clinical benefits.
- Calculated incremental cost-effectiveness ratio (ICER) as cost per life year saved.
Main Results:
- The ThinPrep LBC method 'dominates' conventional Pap smears in average-risk Australian women.
- Model predicts ThinPrep outperforms conventional Pap smears in cervical cancer screening.
- An additional 2240 high-grade lesions could be detected annually.
Conclusions:
- The MSAC health economic model indicates ThinPrep LBC is superior to conventional Pap smears.
- Implementing LBC could result in 480 life years gained annually.
- Replacing conventional Pap smears with LBC is projected to save the Australian healthcare system $5,536,000 per annum.